BACKGROUND: Allergic asthma is a major cause of worldwide morbidity and results from inadequate immune regulation in response to innocuous, environmental antigens. The need exists to understand the mechanisms that promote nonreactivity to human-relevant allergens such as house dust mite (HDM) in order to develop curative therapies for asthma. The aim of our study was to compare the effects of short-, intermediate- and long-term HDM administration in a murine asthma model and determine the ability of long-term HDM exposure to suppress allergic inflammation. METHODS: C57BL/6 mice were intranasally instilled with HDM for short-term (2 weeks), intermediate-term (5 weeks) and long-term (11 weeks) periods to induce allergic airway disease (AAD). The severity of AAD was compared across all stages of the model via both immunological and pulmonary parameters. RESULTS: Short- and intermediate-term HDM exposure stimulated the development of AAD that included eosinophilia in the bronchoalveolar lavage fluid (BALF), pronounced airway hyperreactivity (AHR) and evidence of lung inflammation. Long-term HDM exposure promoted the suppression of AAD, with a loss of BALF eosinophilia and AHR despite persistent mononuclear inflammation in the lungs. Suppression of AAD with long-term HDM exposure was associated with an increase in both Foxp3+ regulatory T cells and IL-10-positive alveolar macrophages at the site of inflammation. CONCLUSIONS: This model recapitulates the key features of human asthma and may facilitate investigation into the mechanisms that promote immunological tolerance against clinically relevant aeroallergens.
BACKGROUND:Allergic asthma is a major cause of worldwide morbidity and results from inadequate immune regulation in response to innocuous, environmental antigens. The need exists to understand the mechanisms that promote nonreactivity to human-relevant allergens such as house dust mite (HDM) in order to develop curative therapies for asthma. The aim of our study was to compare the effects of short-, intermediate- and long-term HDM administration in a murineasthma model and determine the ability of long-term HDM exposure to suppress allergic inflammation. METHODS: C57BL/6 mice were intranasally instilled with HDM for short-term (2 weeks), intermediate-term (5 weeks) and long-term (11 weeks) periods to induce allergic airway disease (AAD). The severity of AAD was compared across all stages of the model via both immunological and pulmonary parameters. RESULTS: Short- and intermediate-term HDM exposure stimulated the development of AAD that included eosinophilia in the bronchoalveolar lavage fluid (BALF), pronounced airway hyperreactivity (AHR) and evidence of lung inflammation. Long-term HDM exposure promoted the suppression of AAD, with a loss of BALF eosinophilia and AHR despite persistent mononuclear inflammation in the lungs. Suppression of AAD with long-term HDM exposure was associated with an increase in both Foxp3+ regulatory T cells and IL-10-positive alveolar macrophages at the site of inflammation. CONCLUSIONS: This model recapitulates the key features of humanasthma and may facilitate investigation into the mechanisms that promote immunological tolerance against clinically relevant aeroallergens.
Authors: Omid Akbari; Gordon J Freeman; Everett H Meyer; Edward A Greenfield; Tammy T Chang; Arlene H Sharpe; Gerald Berry; Rosemarie H DeKruyff; Dale T Umetsu Journal: Nat Med Date: 2002-07-29 Impact factor: 53.440
Authors: Jeffrey T McNamara; Craig M Schramm; Anurag Singh; Eric R Secor; Linda A Guernsey; Leo Lefrançois; Roger S Thrall Journal: Am J Pathol Date: 2012-03-24 Impact factor: 4.307
Authors: Filip K Swirski; Dusan Sajic; Clinton S Robbins; Beata U Gajewska; Manel Jordana; Martin R Stämpfli Journal: J Immunol Date: 2002-10-01 Impact factor: 5.422
Authors: Chris L Van Hove; Tania Maes; Didier D Cataldo; Maud M Guéders; Els Palmans; Guy F Joos; Kurt G Tournoy Journal: Int Arch Allergy Immunol Date: 2009-02-12 Impact factor: 2.749
Authors: William F Carson; Linda A Guernsey; Anurag Singh; Anthony T Vella; Craig M Schramm; Roger S Thrall Journal: Int Arch Allergy Immunol Date: 2007-10-04 Impact factor: 2.749
Authors: Kazuki Furuhashi; Yen L Chua; Kenneth H S Wong; Qian Zhou; Debbie C P Lee; Ka H Liong; Guo H Teo; Paul E Hutchinson; David M Kemeny Journal: Immunology Date: 2017-04-03 Impact factor: 7.397
Authors: C B Mathias; C M Schramm; L A Guernsey; C A Wu; S H Polukort; J Rovatti; J Ser-Dolansky; E Secor; S S Schneider; R S Thrall; H L Aguila Journal: Clin Exp Allergy Date: 2017-02-07 Impact factor: 5.018
Authors: Mina Youssef; Juan B De Sanctis; Cynthia Kanagaratham; Shao Tao; Eisha Ahmed; Danuta Radzioch Journal: Pharm Res Date: 2020-01-08 Impact factor: 4.200
Authors: Tyler D Gavitt; Alyssa K Hartmann; Shraddha S Sawant; Arlind B Mara; Steven M Szczepanek; Jessica L Rouge Journal: ACS Nano Date: 2021-06-23 Impact factor: 18.027